Abstract
Introduction A few cases of serious side effects have been reported of Momordica charantia L. (MC). No comprehensive safety assessment has yet been performed based on human intake.This systematic review aims to evaluate the potential harm of Momordica charantia L. derived products using data from randomized controlled trials.
Methods Databases Cochrane Library, Pubmed and EMBASE were searched until December 2020. The PRISMA harms checklist was followed. Data extraction was on aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, adverse effects (AE), reasons for drop out related to the intervention and interaction with other treatment. Two authors independently extracted data and bias was evaluated based on the latest version of the Cochrane risk of Bias Tool (RoB 2). Additional safety data were requested from Health Regulatory Agencies, Herbal Medicine Associations and manufacturers.
Results Seventeen trials met the inclusion criteria. The IRR was calculated for each study ranging from 0.30 (95% CI = 0.12 to 0.75) to 13.00 (95% CI = 0.73 to 230.76) of any adverse events.
Conclusions Under a daily dosage of 6g of MC-derived products no evidence was seen of harms in humans. In case reports that showed serious harm, MC was used in a liquid form. The safety of traditional MC-based supplements appears more guaranteed when produced under strict quality standards.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/
Funding Statement
The project was financially supported by the EFRO project Kansen voor West Green Health Solutions (KVW00117) and the Dutch Ministry of Agriculture, Nature and Food Quality project code EU-TU-18007.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data in the present study are available from previous publications.
List of abbreviations
- AE
- adverse events
- AF
- atrial fibrillation
- ALT
- alanine aminotransferase
- AST
- aspartate aminotransferase
- BMI
- body mass index
- CAERS
- centre adverse events reporting system
- CI
- confidence interval
- CFSAN
- Center for Food Safety and Applied Nutrition
- EFSA
- European food and safety authority
- FDA
- food and drug administration
- FPG
- fast plasma glucose
- GABA
- gamma-aminobutyric acid
- GMP
- good manufacturing practice
- G6PD
- glucose-6-phosphate dehydrogenase
- g
- gram
- Hb
- hemaglobin
- HbA1c
- glycosylated hemoglobin Type A1C,
- IRR
- incidence rate ratio
- MC
- Momordica charantia
- mcIRBP-19
- peptideB19 amino acids mcIRBP-19
- mg
- milligram
- ml
- milliliter
- mmol/L
- millimoles per litre
- N
- number
- OAA
- oral diabetic agent
- PPG
- postprandial glucose
- ppm
- parts per million
- RCT
- randomized controlled trial
- TCM
- traditional Chinese medicine
- T2DM
- type-2 diabetes mellitus
- WHO
- world health organization
- wks
- weeks
- w/v
- weight per volume
- w/w
- weight per weight
